Innovative Therapies for Complex Diseases
Repligen's Development Pipeline

Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development programs:

• SecreFlo(TM), synthetic human secretin, positive Phase 3 study completed to improve magnetic resonance imaging of the pancreas
• SecreFlo(TM), synthetic human secretin, investigator led pilot studies to improve pancreatic cancer detection
• RG3039, promoters of SMN2 gene expression, entering Phase 1 for spinal muscular atrophy
• RG2833, HDAC (Class 1) inhibitors, in preclinical development for Friedreich's ataxia